抗癌藥物之篩選方法及治療癌症之方法

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

102141507

專利證號

I 522616

專利獲證名稱

抗癌藥物之篩選方法及治療癌症之方法

專利所屬機關 (申請機關)

國立臺灣大學

獲證日期

2016/02/21

技術說明

本發明包括二部份，第一:利用穩定的Q-RT-PCR系統，測定二個特定mRNA表現量技術，可用於預測與快速篩選藥物在肝癌細胞株抗癌之反應，藉此當作快速篩選抗癌藥物之平台。第二: 利用第一部份平台，目前找出GADD45b和GADD45g增強劑的前導化合物“SC-20”，目前我們証實SC-20不論在對sorafenib有效或有抗藥性的肝癌細胞中均顯示明顯療效，進一步的動物實驗更証明有優於sorafenib對抗肝細胞癌之效果，且初步証實具有免疫活化的作用，另外在藥物動力學實驗更發現SC-20可安全、長效、高劑量在血漿中表現，所以將來可望運用於肝癌或其它癌症之治療，相信能有很大的競爭力。 The present invention includes two parts: Firstly, the use of stable Q-RT-PCR system, measuring the two mRNAs techniques can be used to predict response and rapid screening the anticancer drugs in hepatocellular carcinoma cell line, whereby as fast screening platform of anti-cancer drugs. Secondly, the use of the first part of the platform, to identify lead compounds. Currently, we found "SC-20", GADD45b and GADD45g agonist, and confirm SC-20 showed significant effects in sorafenib-sensitive and sorafenib-resistant HCC cell lines. Further animal experiments proved more than sorafenib in hepatocellular carcinoma. Preliminary results, SC-20 was be found the role of immune activation, in addition to the pharmacokinetic experiments also found that SC-20 is safe, long-term, high- dose in rat plasma. Therefore, the future is expected to apply the treatment of liver cancer or other cancers, I believe that there are very competitive.

備註

連絡單位 (專責單位/部門名稱)

產學合作總中心

連絡電話

33669945

網址